Comparing the current results to its competitors, Embecta reported Revenue decrease in the 3 quarter 2026 year on year by -7.93 %, despite the revenue increase by the most of its competitors of 4.39 %, recorded in the same quarter.
Embecta 's Comment on Competition and Industry Peers
The company operates in the diabetes care industry, competing in various therapies and administration methods for diabetes management. Its competitors in the diabetes drug injection sector include Novo Nordisk, MTD Group, and Terumo Medical Corporation. The company also competes with providers of insulin pumps and other insulin administration devices. Key competitive factors include product quality, clinical innovation, price, service, reputation, and commercial execution.
Dexcom Incs business model focuses on developing and selling continuous glucose monitoring systems for diabetes management. Their products provide real-time glucose level tracking, enabling users to better manage their condition through data-driven insights.
Tandem Diabetes Care Inc is a medical device company that specializes in designing, manufacturing, and marketing insulin pumps. Their business model revolves around developing and selling technologically advanced insulin delivery systems to improve the quality of life for individuals with diabetes. By constantly innovating and focusing on customer needs, Tandem Diabetes Care Inc aims to capture a significant portion of the insulin pump market and establish itself as a trusted leader in the industry.
Insulet Corporation operates under a business model where they design, develop, and market innovative tubeless insulin delivery systems for people with diabetes. Their main product, the Omnipod System, is a wearable device that provides continuous insulin delivery without the need for traditional insulin pumps and tubing. This unique business model focuses on improving the quality of life for individuals with diabetes by offering a convenient and user-friendly insulin management solution.
Modular Medical Inc operates with a business model focused on designing and manufacturing modular medical units, offering cost-effective and customizable solutions for healthcare providers looking to expand their facilities rapidly and efficiently. They aim to deliver innovative and turnkey solutions that can be easily deployed and scaled to meet the specific needs of their clients.
Medtronic Plc operates a global business model centered on the development and distribution of advanced medical technologies across four key segments: Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies, and Diabetes. The company emphasizes innovation and collaboration with healthcare providers to enhance patient outcomes and drive efficiency within healthcare systems.
Sources:
Embecta Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Embecta Corp versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
